Literature DB >> 32747684

Salvage second transplantation in relapsed multiple myeloma.

Binod Dhakal1, Anita D'Souza2, Ariel Kleman2, Saurabh Chhabra2, Meera Mohan3, Parameswaran Hari2.   

Abstract

Entities:  

Year:  2020        PMID： 32747684      PMCID： PMC8020391          DOI： 10.1038/s41375-020-1005-8

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.

Authors:  Leopold Sellner; Christiane Heiss; Axel Benner; Marc S Raab; Jens Hillengass; Dirk Hose; Nicola Lehners; Gerlinde Egerer; Anthony D Ho; Hartmut Goldschmidt; Kai Neben
Journal:  Cancer       Date:  2013-04-10       Impact factor: 6.860

2.  Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.

Authors:  Ursina Gössi; Barbara Jeker; Behrouz Mansouri Taleghani; Ulrike Bacher; Urban Novak; Daniel Betticher; Thomas Egger; Thilo Zander; Thomas Pabst
Journal:  Hematol Oncol       Date:  2018-01-24       Impact factor: 5.271

3.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Authors:  Meletios A Dimopoulos; Albert Oriol; Hareth Nahi; Jesus San-Miguel; Nizar J Bahlis; Saad Z Usmani; Neil Rabin; Robert Z Orlowski; Mieczyslaw Komarnicki; Kenshi Suzuki; Torben Plesner; Sung-Soo Yoon; Dina Ben Yehuda; Paul G Richardson; Hartmut Goldschmidt; Donna Reece; Steen Lisby; Nushmia Z Khokhar; Lisa O'Rourke; Christopher Chiu; Xiang Qin; Mary Guckert; Tahamtan Ahmadi; Philippe Moreau
Journal:  N Engl J Med       Date:  2016-10-06       Impact factor: 91.245

4.  Salvage second hematopoietic cell transplantation in myeloma.

Authors:  Laura C Michaelis; Ayman Saad; Xiaobo Zhong; Jennifer Le-Rademacher; Cesar O Freytes; David I Marks; Hillard M Lazarus; Jennifer M Bird; Leona Holmberg; Rammurti T Kamble; Shaji Kumar; Michael Lill; Kenneth R Meehan; Wael Saber; Jeffrey Schriber; Jason Tay; Dan T Vogl; Baldeep Wirk; Bipin N Savani; Robert P Gale; David H Vesole; Gary J Schiller; Muneer Abidi; Kenneth C Anderson; Taiga Nishihori; Matt E Kalaycio; Julie M Vose; Jan S Moreb; William Drobyski; Reinhold Munker; Vivek Roy; Armin Ghobadi; H Kent Holland; Rajneesh Nath; L Bik To; Angelo Maiolino; Adetola A Kassim; Sergio A Giralt; Heather Landau; Harry C Schouten; Richard T Maziarz; Joseph Mikhael; Tamila Kindwall-Keller; Patrick J Stiff; John Gibson; Sagar Lonial; Amrita Krishnan; Angela Dispenzieri; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-05       Impact factor: 5.742

5.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Authors:  Antonio Palumbo; Asher Chanan-Khan; Katja Weisel; Ajay K Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria V Mateos; Tomer M Mark; Ming Qi; Jordan Schecter; Himal Amin; Xiang Qin; William Deraedt; Tahamtan Ahmadi; Andrew Spencer; Pieter Sonneveld
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

6.  Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.

Authors:  Holger W Auner; Richard Szydlo; Alero Rone; Aristeidis Chaidos; Chrissy Giles; Ed Kanfer; Donald H Macdonald; David Marin; Dragana Milojkovic; Jiri Pavlu; Jane F Apperley; Amin Rahemtulla
Journal:  Leuk Lymphoma       Date:  2013-03-04

7.  The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Authors:  Gordon Cook; A John Ashcroft; David A Cairns; Cathy D Williams; Julia M Brown; Jamie D Cavenagh; John A Snowden; Christopher Parrish; Kwee Yong; Jim Cavet; Hannah Hunter; Jenny M Bird; Guy Pratt; Sally Chown; Ernest Heartin; Sheila O'Connor; Mark T Drayson; Anna Hockaday; Treen C M Morris
Journal:  Lancet Haematol       Date:  2016-07       Impact factor: 18.959

Review 8.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

9.  Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.

Authors:  Binod Dhakal; Aniko Szabo; Saurabh Chhabra; Mehdi Hamadani; Anita D'Souza; Saad Z Usmani; Rita Sieracki; Bishal Gyawali; Jeffrey L Jackson; Fotis Asimakopoulos; Parameswaran N Hari
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

Review 10.  Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Authors:  C S Chim; S K Kumar; R Z Orlowski; G Cook; P G Richardson; M A Gertz; S Giralt; M V Mateos; X Leleu; K C Anderson
Journal:  Leukemia       Date:  2017-11-16       Impact factor: 11.528
View more
  5 in total

Review 1.  Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.

Authors:  Shaji Kumar; Lawrence Baizer; Natalie S Callander; Sergio A Giralt; Jens Hillengass; Boris Freidlin; Antje Hoering; Paul G Richardson; Elena I Schwartz; Anthony Reiman; Suzanne Lentzsch; Philip L McCarthy; Sundar Jagannath; Andrew J Yee; Richard F Little; Noopur S Raje
Journal:  Blood Cancer J       Date:  2022-06-29       Impact factor: 9.812

Review 2.  The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.

Authors:  José-Ángel Hernández-Rivas; Rafael Ríos-Tamayo; Cristina Encinas; Rafael Alonso; Juan-José Lahuerta
Journal:  Biomark Res       Date:  2022-01-09

3.  Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT.

Authors:  Joanna Drozd-Sokołowska; Luuk Gras; Nienke Zinger; John A Snowden; Mutlu Arat; Grzegorz Basak; Anastasia Pouli; Charles Crawley; Keith M O Wilson; Herve Tilly; Jennifer Byrne; Claude Eric Bulabois; Jakob Passweg; Zubeyde Nur Ozkurt; Wilfried Schroyens; Bruno Lioure; Mercedes Colorado Araujo; Xavier Poiré; Gwendolyn Van Gorkom; Gunhan Gurman; Liesbeth C de Wreede; Patrick J Hayden; Meral Beksac; Stefan O Schönland; Ibrahim Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2022-02-15       Impact factor: 5.483

4.  Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.

Authors:  Christopher Lemieux; Lori S Muffly; David J Iberri; Juliana K Craig; Laura J Johnston; Robert Lowsky; Parveen Shiraz; Andrew R Rezvani; Matthew J Frank; Wen-Kai Weng; Everett Meyer; Judith A Shizuru; Sally Arai; Michaela Liedtke; Robert S Negrin; David B Miklos; Surbhi Sidana
Journal:  Bone Marrow Transplant       Date:  2021-06-23       Impact factor: 5.174

5.  Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.

Authors:  Kristin Larsen; Horace Spencer; Meera Mohan; Clyde Bailey; Kerri Hill; Mathew Kottarathara; Richa Parikh; Shadiqul Hoque; Amani Erra; Angel A Mitma; Pankaj Mathur; Lakshmi Yarlagadda; Sravani Gundarlapalli; Yetunde Ogunsesan; Munawwar Hussain; Nishanth Thalambedu; Jaskirat Sehti; Samer Al Hadidi; Sharmilan Thanendrarajan; Monica Graziutti; Maurizio Zangari; Bart Barlogie; Frits van Rhee; Guido Tricot; Carolina Schinke
Journal:  J Clin Med       Date:  2022-03-16       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.